CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment

We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.

Using CANTAB to investigate age-related cognitive changes associated with dementia in Down syndrome

PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.

Neural Network classification of longitudinal cognitive data for prediction of individual-level chan

For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018

CANTAB Mobile: experience of use of a digital memory assessment tool in UK primary care

Cambridge Cognition presented new data at AAIC 2018 that demonstrates a demand from patients for the objective assessment of memory function, and describes how CANTAB testing can triage these memory complaints in clinic.

CANTAB technology selected for world’s largest dementia study

We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.

CANTAB Recruit software to be used in two major Phase III drug trials

​We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.

What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?

The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development. 

WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease

Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.

Join them to hear more about overcoming the barriers to expedite the drug development process.

Tuesday 22nd May 2018, 11 a.m. EDT

Speech recognition and online assessments: the future for clinical trials in Alzheimer's disease?

New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.

The CANTAB Paired Associates Learning task as a pre-screening tool for clinical trials

Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.

Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials

Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?

Alzheimer's research technology showcase - AAIC 2017

Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.

Paired Associates Learning: Adding Sensitivity By Measuring Reaction Times

Computerised testing brings an unprecedented ability to capture more detailed information about patient responses. This could provide novel insights into cognitive processes, and greater discriminatory power in predicting cognitive deficits and decline in Alzheimer's and other diseases.

Feasibility of automated voice based cognitive assessment on a consumer voice platform

Exploring the use of automated voice based cognitive assessments on consumer voice platforms.

Cognition and Alzheimer's Technology at AAIC 2017

Cambridge Cognition is attending the Alzheimer's Association International Conference in London.

Evaluating familiarity deficits related to conversion of MCI to Alzheimer’s disease

The early identification of individuals at risk of Alzheimer's Disease (AD) is of primary importance for the development of new effective interventions to stop the progression of the disease before the onset of severe neurodegeneration and clinical manifestations. 

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, test-retest, technology, swm, subjective measures, stigma, spatial planning, social cognition, smartphones, set-shifting, schizophrenia research, schizophrenia, rvp, rule learning, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, precision psychiatry, pre-clinical, pharmacovigilance, personalised medicine, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health, mci, major depression, machine learning, lifespan, inpatients, ied, high frequency, healthcare, ert, episodic memory, epidemiology, emotion recognition, efficacy, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, dopamine, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, clinical symptoms, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, affective cognition, absenteeism,